Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells

Korean Journal of Hematology

Volumn 47, Issue 3, 2012, Pages 178-185

  Kim, Soo Jeong ^a   Jang, Ji Eun ^a   Cheong, June Won ^a   Eom, Ju In ^a   Jeung, Hoi Kyung ^a   Kim, Yundeok ^a   Hwang, Doh Yu ^a   Min, Yoo Hong ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Acute myeloid leukemia; Aurora kinase; Leukemia stem cell

Indexed keywords

AURORA A KINASE; AURORA KINASE INHIBITOR; C 1368; CD34 ANTIGEN; CD38 ANTIGEN; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CYTOTOXICITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN EXPRESSION; STEM CELL;

EID: 84874092965     PISSN: 17387949     EISSN: 20929129     Source Type: Journal    
DOI: 10.5045/kjh.2012.47.3.178     Document Type: Article

References (19)

1. Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 2003;15: 672-83.
2. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54.
3. Gritsko TM, Coppola D, Paciga JE, et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003;9:1420-6.
4. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004;10:2065-71.
5. Kurai M, Shiozawa T, Shih HC, et al. Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 2005;36:1281-8.
6. Reiter R, Gais P, Jütting U, et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:5136-41.
7. Lassus H, Staff S, Leminen A, Isola J, Butzow R. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol 2011;120:11-7.
8. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008;1786:60-72.
9. Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol 2011;155:561-79.
10. Cammareri P, Scopelliti A, Todaro M, et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 2010;70:4655-65.
11. Chefetz I, Holmberg JC, Alvero AB, Visintin I, Mor G. Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFκB pathway. Cell Cycle 2011;10:2206-14.
12. Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010;28:275-80.
13. Testa U. Leukemia stem cells. Ann Hematol 2011;90:245-71.
14. Cheong JW, Jung HI, Eom JI, Kim SJ, Jeung HK, Min YH. Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe. Cancer Lett 2010;297:171-81.
15. Wang J, Yang S, Zhang H, et al. Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep 2011;26:23-32.
16. Fajtova M, Babusikova O. Immunophenotype characterization of hematopoietic stem cells, progenitor cells restricted to myeloid lineage and their leukemia counterparts. Neoplasma 2010;57:392-400.
17. Ye D, Garcia-Manero G, Kantarjian HM, et al. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop 2009;2:2-8.
18. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factorkappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98:2301-7.
19. Colado E, Alvarez-Fernández S, Maiso P, et al. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica 2008;93:57-66.